VANDA PHARMACEUTICALS INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
VANDA PHARMACEUTICALS INC. (VNDA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $121.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-02-12
- VANDA PHARMACEUTICALS INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $121.00K, a 32.02% decline from fiscal 2024.
- VANDA PHARMACEUTICALS INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was $178.00K, a 212.28% increase from fiscal 2023.
- VANDA PHARMACEUTICALS INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2023 was $57.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | $121.00K 10-K · filed 2026-02-12 |
| 2024-12-31 | $178.00K 10-K · filed 2026-02-12 |
| 2023-12-31 | $57.00K 10-K · filed 2026-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |